Perrigo Company plc (PRGO) Stock Analysis
Falling Knife setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $10.68: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum.
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including... Read more
Sell if holding. Engine safety override at $10.68: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Score 5.0/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Perrigo Company plc
Latest news
- Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- Perrigo Reports Q1 2026 Results: Full Earnings Call Transcript — benzinga May 6, 2026 neutral
- Perrigo Affirms FY2026 Adj EPS Guidance of $2.25-$2.55 vs $2.11 Est; Affirms FY2026 Sales Guidance of $4.019B-$4.189B vs — benzinga May 6, 2026 positive
- Perrigo Q1 Adj. EPS $0.43 Beats $0.31 Estimate, Sales $939.000M Miss $1.031B Estimate — benzinga May 6, 2026 positive
- FDA Takes Step Forward on Testosterone Therapy for Men — benzinga Apr 16, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -43.5%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.68: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Prior stop was $10.20. Score 5.0/10, moderate confidence.
Take-profit target: $14.03 (+31.4% upside). Prior stop was $10.20. Stop-loss: $10.20.
Quality below floor (3.0 < 4.0).
Perrigo Company plc trades at a P/E of N/A (forward 4.5). TrendMatrix value score: 9.2/10. Verdict: Sell.
10 analysts cover PRGO with a consensus score of 3.8/5. Average price target: $17.
What does Perrigo Company plc do?Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and...
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.